| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 8 | 2013 | 311 | 1.270 |
Why?
|
| Kidney | 8 | 2013 | 1145 | 1.100 |
Why?
|
| Hypertension | 2 | 2019 | 741 | 0.880 |
Why?
|
| Endotoxemia | 3 | 2012 | 18 | 0.870 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2013 | 699 | 0.870 |
Why?
|
| Kidney Glomerulus | 6 | 2013 | 122 | 0.690 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2019 | 20 | 0.690 |
Why?
|
| Apolipoprotein L1 | 1 | 2019 | 7 | 0.690 |
Why?
|
| Tetrazoles | 1 | 2019 | 24 | 0.680 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 46 | 0.680 |
Why?
|
| Complement Activation | 6 | 2015 | 81 | 0.670 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 126 | 0.660 |
Why?
|
| Benzimidazoles | 1 | 2019 | 111 | 0.640 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 557 | 0.620 |
Why?
|
| Colistin | 2 | 2017 | 7 | 0.600 |
Why?
|
| Lipopolysaccharides | 7 | 2013 | 293 | 0.580 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 249 | 0.560 |
Why?
|
| Pharmacogenetics | 2 | 2019 | 443 | 0.520 |
Why?
|
| Nephritis | 2 | 2018 | 17 | 0.490 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 66 | 0.440 |
Why?
|
| Urothelium | 1 | 2013 | 71 | 0.430 |
Why?
|
| Mice, Inbred C57BL | 12 | 2013 | 3211 | 0.430 |
Why?
|
| Sepsis | 3 | 2013 | 319 | 0.430 |
Why?
|
| Tight Junction Proteins | 1 | 2012 | 14 | 0.420 |
Why?
|
| Tight Junctions | 2 | 2015 | 150 | 0.410 |
Why?
|
| Endothelial Cells | 3 | 2015 | 459 | 0.390 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2009 | 73 | 0.380 |
Why?
|
| Caspase 8 | 1 | 2009 | 34 | 0.340 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2009 | 41 | 0.330 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 55 | 0.330 |
Why?
|
| Mice | 19 | 2014 | 11742 | 0.320 |
Why?
|
| Kidney Transplantation | 4 | 2019 | 849 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2019 | 2399 | 0.260 |
Why?
|
| Receptors, Cell Surface | 2 | 2004 | 289 | 0.250 |
Why?
|
| Complement C5a | 2 | 2015 | 24 | 0.250 |
Why?
|
| Animals | 22 | 2014 | 27324 | 0.250 |
Why?
|
| Kidney Tubules | 3 | 2013 | 92 | 0.250 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2005 | 23 | 0.250 |
Why?
|
| Caspases | 1 | 2004 | 155 | 0.240 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 432 | 0.240 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2013 | 43 | 0.240 |
Why?
|
| Complement C3 | 4 | 2002 | 58 | 0.220 |
Why?
|
| Apoptosis | 6 | 2009 | 1717 | 0.220 |
Why?
|
| Graft Rejection | 2 | 2019 | 1067 | 0.210 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 90 | 0.200 |
Why?
|
| Receptors, Complement | 4 | 2002 | 46 | 0.190 |
Why?
|
| Disease Models, Animal | 5 | 2014 | 2362 | 0.190 |
Why?
|
| Glomerulonephritis | 1 | 2001 | 76 | 0.190 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2000 | 23 | 0.190 |
Why?
|
| Male | 15 | 2019 | 42254 | 0.180 |
Why?
|
| Antigens, CD | 1 | 2002 | 466 | 0.180 |
Why?
|
| Biological Variation, Individual | 1 | 2019 | 7 | 0.170 |
Why?
|
| Blood-Brain Barrier | 3 | 2015 | 74 | 0.170 |
Why?
|
| Gene Targeting | 1 | 2019 | 73 | 0.170 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 59 | 0.170 |
Why?
|
| Pharmacogenomic Variants | 1 | 2019 | 42 | 0.170 |
Why?
|
| Fatal Outcome | 1 | 2019 | 299 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2019 | 119 | 0.160 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 121 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 105 | 0.160 |
Why?
|
| Albuminuria | 2 | 2013 | 48 | 0.160 |
Why?
|
| Bowman Capsule | 1 | 2018 | 6 | 0.160 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 179 | 0.160 |
Why?
|
| Signal Transduction | 1 | 2009 | 3374 | 0.160 |
Why?
|
| Tacrolimus | 1 | 2019 | 369 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1429 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2019 | 948 | 0.150 |
Why?
|
| Complement Inactivator Proteins | 3 | 2002 | 27 | 0.150 |
Why?
|
| Renal Dialysis | 2 | 2018 | 335 | 0.150 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 178 | 0.150 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2009 | 53 | 0.140 |
Why?
|
| Mice, Knockout | 5 | 2013 | 1990 | 0.140 |
Why?
|
| Neutrophil Infiltration | 2 | 2009 | 28 | 0.140 |
Why?
|
| Income | 1 | 2017 | 83 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2015 | 210 | 0.140 |
Why?
|
| Genome-Wide Association Study | 3 | 2019 | 1670 | 0.130 |
Why?
|
| Neutrophils | 4 | 2007 | 308 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 866 | 0.130 |
Why?
|
| Minority Groups | 1 | 2017 | 144 | 0.130 |
Why?
|
| Enzyme Activation | 2 | 2009 | 698 | 0.130 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2015 | 21 | 0.130 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 1223 | 0.130 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1975 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2019 | 899 | 0.120 |
Why?
|
| Genotype | 1 | 2019 | 1848 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 975 | 0.120 |
Why?
|
| Homeodomain Proteins | 2 | 2017 | 556 | 0.120 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2015 | 78 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2017 | 423 | 0.110 |
Why?
|
| Galectin 3 | 1 | 2013 | 17 | 0.110 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2013 | 67 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 122 | 0.110 |
Why?
|
| Communication | 1 | 2017 | 457 | 0.110 |
Why?
|
| Brain | 3 | 2015 | 2281 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 424 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 63 | 0.110 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 39 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2015 | 2880 | 0.110 |
Why?
|
| Necrosis | 1 | 2013 | 209 | 0.110 |
Why?
|
| Immunoglobulin G | 4 | 2002 | 464 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 413 | 0.110 |
Why?
|
| Genes | 1 | 2013 | 305 | 0.100 |
Why?
|
| Kidney Tubules, Distal | 1 | 2012 | 19 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 371 | 0.100 |
Why?
|
| Humans | 10 | 2019 | 89073 | 0.100 |
Why?
|
| Cytosine | 1 | 2013 | 128 | 0.100 |
Why?
|
| Transcription Factor RelA | 2 | 2009 | 49 | 0.100 |
Why?
|
| Body Weight | 1 | 2013 | 452 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 625 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 786 | 0.100 |
Why?
|
| Female | 6 | 2019 | 46014 | 0.100 |
Why?
|
| Reperfusion Injury | 2 | 2002 | 140 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 841 | 0.090 |
Why?
|
| Cell Line | 4 | 2017 | 2495 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2019 | 8203 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2014 | 551 | 0.090 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2009 | 42 | 0.080 |
Why?
|
| Myosin Light Chains | 1 | 2009 | 29 | 0.080 |
Why?
|
| Caspase Inhibitors | 1 | 2009 | 33 | 0.080 |
Why?
|
| NF-kappa B | 2 | 2015 | 466 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2009 | 56 | 0.080 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 54 | 0.080 |
Why?
|
| Mice, Transgenic | 4 | 2007 | 1574 | 0.080 |
Why?
|
| Receptors, Complement 3b | 4 | 2002 | 39 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 507 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2017 | 1652 | 0.080 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2009 | 85 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2412 | 0.080 |
Why?
|
| Clusterin | 1 | 2007 | 13 | 0.080 |
Why?
|
| bcl-X Protein | 1 | 2007 | 54 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2009 | 426 | 0.080 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2007 | 8 | 0.070 |
Why?
|
| Aged | 3 | 2019 | 19078 | 0.070 |
Why?
|
| CD18 Antigens | 1 | 2007 | 22 | 0.070 |
Why?
|
| Endotoxins | 1 | 2007 | 36 | 0.070 |
Why?
|
| Adult | 4 | 2019 | 26508 | 0.070 |
Why?
|
| Kidney Diseases | 2 | 2007 | 319 | 0.070 |
Why?
|
| Encephalitis | 1 | 2007 | 104 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2752 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2007 | 87 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2009 | 1130 | 0.070 |
Why?
|
| Middle Aged | 3 | 2019 | 25865 | 0.060 |
Why?
|
| Complement System Proteins | 2 | 2002 | 83 | 0.060 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2004 | 25 | 0.060 |
Why?
|
| Gene Expression | 3 | 2013 | 1310 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 604 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 192 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 101 | 0.060 |
Why?
|
| Cell Movement | 1 | 2007 | 783 | 0.060 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 91 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 371 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 92 | 0.050 |
Why?
|
| Rats | 4 | 2002 | 4041 | 0.050 |
Why?
|
| Glomerular Mesangium | 1 | 2002 | 18 | 0.050 |
Why?
|
| CD55 Antigens | 1 | 2002 | 21 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2002 | 433 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2002 | 20 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2002 | 18 | 0.050 |
Why?
|
| Species Specificity | 1 | 2004 | 684 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 126 | 0.050 |
Why?
|
| Complement C5b | 1 | 2001 | 2 | 0.050 |
Why?
|
| Heymann Nephritis Antigenic Complex | 1 | 2001 | 3 | 0.050 |
Why?
|
| Complement C3b | 1 | 2001 | 5 | 0.050 |
Why?
|
| Complement C3d | 1 | 2001 | 6 | 0.050 |
Why?
|
| CD59 Antigens | 1 | 2001 | 17 | 0.050 |
Why?
|
| Complement C5 | 1 | 2001 | 14 | 0.050 |
Why?
|
| Transgenes | 1 | 2002 | 185 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2001 | 71 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2001 | 103 | 0.050 |
Why?
|
| Astrocytes | 2 | 2015 | 141 | 0.050 |
Why?
|
| Complement Factor H | 1 | 2001 | 34 | 0.050 |
Why?
|
| Renal Circulation | 1 | 2001 | 48 | 0.050 |
Why?
|
| Lupus Nephritis | 1 | 2002 | 77 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2001 | 150 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2001 | 135 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2004 | 429 | 0.040 |
Why?
|
| Time Factors | 1 | 2009 | 5320 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Ischemia | 1 | 2001 | 251 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 565 | 0.040 |
Why?
|
| Risk Factors | 2 | 2019 | 5466 | 0.040 |
Why?
|
| Allografts | 1 | 2018 | 181 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2017 | 232 | 0.030 |
Why?
|
| Junctional Adhesion Molecules | 1 | 2015 | 3 | 0.030 |
Why?
|
| Claudin-5 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Graft Survival | 1 | 2019 | 898 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 1401 | 0.030 |
Why?
|
| United States | 2 | 2019 | 6957 | 0.030 |
Why?
|
| Poverty | 1 | 2017 | 180 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 68 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2015 | 70 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2015 | 110 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 123 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 370 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 396 | 0.030 |
Why?
|
| Permeability | 1 | 2014 | 137 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 582 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1182 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 421 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1488 | 0.030 |
Why?
|
| HapMap Project | 1 | 2013 | 47 | 0.030 |
Why?
|
| Actin Cytoskeleton | 1 | 2015 | 196 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 9237 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 1423 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 948 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1715 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 607 | 0.030 |
Why?
|
| Thiazides | 1 | 2012 | 16 | 0.030 |
Why?
|
| Sodium Chloride Symporters | 1 | 2012 | 13 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3657 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 198 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 410 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 477 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 313 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 638 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 276 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 2553 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2863 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2013 | 681 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2002 | 1237 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2612 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 726 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1662 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2011 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 4273 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 27 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 46 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 41 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2007 | 45 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2007 | 42 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2007 | 65 | 0.020 |
Why?
|
| Aquaporin 4 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Gliosis | 1 | 2007 | 35 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2007 | 38 | 0.020 |
Why?
|
| Brain Edema | 1 | 2007 | 58 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 153 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 2439 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 1371 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 6289 | 0.020 |
Why?
|
| Child | 1 | 2015 | 7149 | 0.010 |
Why?
|
| Nephrosis | 1 | 2002 | 3 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2002 | 29 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 68 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2002 | 9 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2002 | 36 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 2002 | 19 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2002 | 116 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2002 | 254 | 0.010 |
Why?
|
| Receptors, Complement 3d | 1 | 2001 | 14 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2001 | 168 | 0.010 |
Why?
|
| Antibodies | 1 | 2002 | 353 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 418 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 543 | 0.010 |
Why?
|
| Solubility | 1 | 2001 | 179 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 249 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2001 | 268 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2002 | 688 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 1533 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 2062 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 2327 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 738 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 3027 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1241 | 0.010 |
Why?
|